However, other specific anti-Her2 molecules, such as lapatinib, Trastuzumab emtansine (T-DM1), or dual anti-Her2 therapy (pertuzumab and trastuzumab), have not demonstrated similar efficacy against esophageal adenocarcinoma [60,61,62], dictating a more complex downstream signaling pathway activation. Here, ERBB2 is linked to esophageal adenocarcinoma.